Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859604 | 1.00 | REN (0.48) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL1859608 | 1.00 | REN (0.48) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL1859602 | 1.00 | REN (0.48) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL3605918 | 0.92 | GPR119 (0.46) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL9996518 | 0.92 | REN (0.43) | RENGAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL8243022 | 0.92 | GPR119 (0.46) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL3605920 | 0.92 | GPR119 (0.46) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL13502914 | 0.92 | GPR119 (0.46) | RENGAAKMT2AGPR119KDM4E | |
| SCHEMBL8234811 | 0.92 | REN (0.52) | RENGPR119KAT6AKAT5USP30 | |
| SCHEMBL3613196 | 0.89 | REN (0.49) | RENKMT2AGPR119ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183755-A1 | TRICYCLIC PYRIMIDONES | ERASCA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| EP-2834236-B1 | HETEROCYCLYL COMPOUNDS | LUPIN LTD (IN) | 2019-05-22 | — | — | EP | disclosed |
| EP-3463480-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2019-04-10 | — | — | EP | disclosed |
| EP-2834237-B1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-9827247-B2 | Heterocyclyl compounds | LUPIN LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-20170112840-A1 | HETEROCYCLYL COMPOUNDS | LUPIN LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| EP-0826686-A2 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| WO-1997010270-A1 | BETAKETOSULFONIC DERIVATIVES SUITABLE TO THE USE AS POLYMERIZATION PHOTOINITIATORS AND PHOTOPOLYMERIZABLE SYSTEMS CONTAINING THE SAME | LAMBERTI S.P.A. (IT) | 1997-03-20 | — | — | WO | disclosed |
| EP-0434960-B1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA SPA (IT) | 1996-09-18 | — | — | EP | disclosed |
| EP-0466131-B1 | Pyranobenzoxadiazole derivatives | NISSAN CHEMICAL IND LTD (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5304687-A | 1-alkoxy-2,2*-diiodo-diethyl ether which reacts with doxorubicin to yield anthrocycline antibiotics | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-04-19 | — | — | US | disclosed |
| US-5272271-A | Pyranobenzoxadiazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| EP-0466131-A2 | Pyranobenzoxadiazole derivatives | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0434960-A1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA S.p.A. (IT) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991009046-A1 | MORPHOLINYL DERIVATIVES OF DOXORUBICIN AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | REN 3770/4885GAA 143/4885KMT2A 4658/4885 |
| US-20170112840-A1 | HETEROCYCLYL COMPOUNDS | NRAS, MAP3K11, MAP3K1 | REN 230/4885GAA 1543/4885KMT2A 1561/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | REN 3770/4885GAA 143/4885KMT2A 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.